Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance

1 Aug 2009

Abstract excerpt

The HER2-targeted therapy trastuzumab is widely used for the treatment of patients with metastatic breast tumors overexpressing HER2. However, an objective response is observed in only 12% to 24% of patients treated with trastuzumab as a single agent and initial responders regress in <6 months (1-3). The reason for the clinical failure of trastuzumab in this setting remains unclear. Here we show that local lymph...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19671734
DOI: 10.1158/1535-7163.mct-09-0295

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistancePMID 19671734Read ↗

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.Semantic proximity Read ↗

Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.Semantic proximity Read ↗

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.Semantic proximity Read ↗

Role of d16HER2 splice variant in breast cancer stem cellsSemantic proximity Read ↗

The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse.Semantic proximity Read ↗

The landscape of d16HER2 splice variant expression across HER2-positive cancersSemantic proximity Read ↗

Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancerSemantic proximity Read ↗

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.Semantic proximity Read ↗

Serine/Threonine kinase 16 phosphorylates STAT3 and confers a JAK2-Inhibition resistance phenotype in triple-negative breast cancer.Semantic proximity Read ↗

Role of exon-16-deleted HER2 in breast carcinomasSemantic proximity Read ↗

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an<i>ERBB2</i>S310F MutationSemantic proximity Read ↗

A novel splice variant ofHER2 with increased transformation activitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.